MCL1 and lymphoma: Additionally, sorafenib might downregulate Mcl-1 [14], which is implicated in resistance to anticancer drugs and is overexpressed in a significant proportion of diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) [26], thereby restoring lymphoma cell sensitivity to apoptosis.